Article
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
The oncologist - 5 Apr 2022
Popat Sanjay, Hsia Te-Chun, Hung Jen-Yu, Jung Hyun Ae, Shih Jin-Yuan, Park Cheol Kyu, Lee Seung Hyeun, Okamoto Tatsuro, Ahn Hee Kyung, Lee Yong Chul, Sato Yuki, Lee Sung Sook, Mascaux Celine, Daoud Hasan, Märten Angela, Miura Satoru
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations are highly heterogeneous, and developments in detection techniques are helping to identify mutations with little or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.